HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Silence Therapeutics (NASDAQ:SLN) and maintained a price target of $80.
August 17, 2023 | 4:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics (NASDAQ:SLN) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $80.
The reiteration of a 'Buy' rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100